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Proteomic analysis reveals GIT1
as a novel mTOR complex
component critical for
mediating astrocyte survival
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As a critical regulator of cell growth, the mechanistic tar-
get of rapamycin (mTOR) protein operates as part of two
molecularly and functionally distinct complexes. Herein,
we demonstrate that mTOR complex molecular compo-
sition varies in different somatic tissues. In astrocytes
and neural stem cells, we identified G-protein-coupled
receptor kinase-interacting protein 1 (GIT1) as a novel
mTOR-binding protein, creating a unique mTOR com-
plex lacking Raptor and Rictor. Moreover, GIT1 binding
to mTOR is regulated by AKT activation and is essential
for mTOR-mediated astrocyte survival. Together, these
data reveal that mTOR complex function is partly dictat-
ed by its molecuflar composition in different cell types.
Supplemental material is available for this article.
Received February 16, 2016; revised version accepted
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Eukaryotic cell growth relies on the precise coordination
and control by the highly conserved serine/threonine
protein kinase mechanistic target of rapamycin (mTOR).
In response to growth factors, amino acids, oxygen levels,
and stress, mTOR assembles into two functionally and
molecularly distinct multiprotein complexes to regulate
a variety of diverse growth-related cellular processes, in-
cluding mRNA translation (Barbet et al. 1996), ribosomal
biogenesis, transcription (Mayer et al. 2004), cell cycle
progression (Fingar et al. 2004), survival (Paglin et al.
2005), and cytoskeletal dynamics (Jacinto et al. 2004; Sar-
bassov et al. 2004).
Based on studies in mouse embryonic fibroblasts and
nonneural cell lines (HEK293 cells), mTOR has been
shown to interact with either Raptor and the proline-rich
AKT substrate of 40 kDa (PRAS40) to form mTOR com-
plex 1 (mTORC1) or Rictor and the mammalian stress-
activatedmapkinase interacting protein 1 (mSIN1) to gen-
erate mTORC2 (Kim et al. 2002; Sarbassov et al. 2004;
Jacinto et al. 2006; Oshiro et al. 2007). As such, mTORC1
function is critical for the regulation of transcription and
protein translation through phosphorylation of p70-S6
kinase 1 (S6K1) and eukaryotic translation initiation fac-
tor 4E (elF4E)-binding protein 1 (4-EBP1) (Gingras et al.
1998; Hara et al. 1998). In contrast, mTORC2 controls ac-
tin cytoskeleton dynamics and cell survival by signaling
to protein kinase C-α (PKCα), protein kinase B (AKT),
and serum- and glucocorticoid-induced protein kinase 1
(SGK1). Beyond these protein interactors, other mTOR-
binding proteins have been identified, including DEP
domain-containing mTOR-interacting protein (Deptor),
mammalian lethal with SEC13 protein 8 (mLST8), and
protein observed with Rictor (Protor), each with varying
capacities to influence mTOR-dependent function (Kim
et al. 2003; Peterson et al. 2009). While the roles of these
other mTOR complex molecules in cell growth have not
been fully elucidated, it is clear that the mTOR complex
is a central regulator of normal cell biology.
The importance of mTOR function to normal develop-
ment and maintenance is underscored by the identifica-
tion of mutations in genes encoding proteins that nega-
tively regulate mTOR as causative etiologies for several
human neurological diseases, including Neurofibromato-
sis type 1 (NF1), Cowden’s syndrome (PTEN), and tuber-
ous sclerosis complex (TSC). In these disorders, loss of
function of neurofibromin (NF1), PTEN, and tuberin/
hamartin (TSC) lead to mTOR hyperactivation and in-
creased cell growth.While each of these proteins negative-
ly regulates mTOR function, the biological consequences
are distinct. First, the mechanisms underlying tuberin/
hamartin and neurofibrominmTOR suppression are sepa-
rable and reflect different modes of mTOR activation
(Banerjee et al. 2011). As such,Nf1 loss in astrocytes leads
to increased proliferation, whereas Tsc1 loss has no effect
on astrocyte proliferation but results in increased cell size
(Uhlmann et al. 2004). Second, mTOR controls prolifera-
tion distinctly in different cell types. While Tsc1 loss
increases mTOR activation and cell growth in fibroblasts,
it has no effect on astrocyte proliferation despite increased
mTOR activation (Sandsmark et al. 2007; Banerjee
et al. 2010). Third, the composition and function of the
mTOR complex is partly dictated by tissue-specific
constraints. For example, the ability of brainstem, but
not cortical, neural stem cells (NSCs) to increase their pro-
liferation and glial cell differentiation following Nf1 gene
inactivation reflects a fivefold increase in Rictor expres-
sion in brainstem NSCs relative to their cortical counter-
parts (Lee da et al. 2010).
In light of these findings, we sought to define the mo-
lecular composition and functionof themTORcomplex in
the brain. Leveraging a combination of proteomic, genet-
ic, and pharmacological approaches, we identified a novel
AKT-regulated mTOR complex protein (G-protein-cou-
pled receptor kinase-interacting protein 1 [GIT1]) in brain
tissues whose function is essential for mTOR-mediated
astrocyte survival.
Results and Discussion
To characterize the mTOR complex in brain cells, we fo-
cused on astrocytes, since these cells represent the non-
malignant counterpart of the cancer cells in the most
common brain tumor (astrocytoma or glioma). Western
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blotting of whole-cell lysates from wild-type brainstem
astrocytes demonstrated cell type differences in the
expression of known mTOR-binding proteins (Fig. 1A).
While Rictor, Raptor, mSIN1, PRAS40, and mLST8 were
expressed in human HEK293 cells, mouse astrocytes,
and mouse fibroblasts, there was an absence of both Dep-
tor and Protor-1 expression in wild-type mouse astrocytes
and fibroblasts (Supplemental Fig. S1A).
Next, to determine whether the knownmTOR-binding
proteins were contained in the mTOR complex in ner-
vous system cells, mTOR immunoprecipitation was per-
formed. As observed in other cell types, Rictor, Raptor,
mSIN1, PRAS40, and mLST8 were found in mTOR com-
plexes in mouse astrocytes (Fig. 1B), similar to fibroblasts
(Fig. 1C). Since there are two functionally distinct mTOR
complexes, identified by their expression of Raptor and
PRAS40 (mTORC1) or Rictor and mSIN1 (mTORC2), we
performed Raptor and Rictor immunoprecipitations. As
observed in other cell types, both the mTORC1 complex
(Raptor, PRAS40, andmLST8) and themTORC2 complex
(Rictor, mSIN1, and mLST8) were identified in mouse
astrocytes (Fig. 1D).
To identify potential novel astrocyte-specific mTOR-
binding proteins, we performed proteomic analyses on
mTOR immunoprecipitations from wild-type astrocytes.
Using a spectral abundance score of ≥10 (and a spectral
count for nonspecific rabbit IgG = 0) and excluding
known nonspecific binding proteins (Mellacheruvu et al.
2013; Contaminant Repository for Affinity Purification,
http://141.214.172.226, version 1.1), threemTOR-binding
protein candidates were identified (Fig. 2A). Using inde-
pendently prepared mTOR immunoprecipitations, only
endogenous GIT1–mTOR binding was validated (Fig.
2B). Importantly, mTORwas contained in GIT1 immuno-
precipitations (Fig. 2C), and mTOR and GIT1 binding
was observed in HEK293T (293T) cells transfected with
myc-mTOR and Flag-GIT1 (Fig. 2D). We also identified
a known GIT1-binding protein, Rho guanine nucleotide
exchange factor 7 (also called PAK-interacting exchange
factor (β-PIX) (Bagrodia et al. 1999; Zhao et al. 2000), in
mTOR immunoprecipitations (spectral abundance score
= 9), which was subsequently confirmed by immunopre-
cipitation (Supplemental Fig. S2A).
To determine whether the interaction between GIT1
and mTOR was neural cell-specific, GIT1 binding to
mTOR was examined in whole-mouse brainstem tissues,
mouse brainstem NSCs, mouse Nf1−/−; p53−/− NPcis
glioma cells, and 293T cells. GIT1 was expressed and
binds mTOR in 1-d-old (postnatal day 1 [P1]) and 1-mo-
old mouse brainstem tissues (Supplemental Fig. S2B),
NSCs, and NPcis glioma cells (data not shown) as well
as in 293T cells, albeit at 100-fold reduced levels (Supple-
mental Fig. S2C). In this regard, GIT1 was predominately
expressed in the brain (the cortex, cerebellum, and olfacto-
ry bulb) relative to nonneural tissues (the liver, kidney,
and heart) (Supplemental Fig. S2D).
Next, to ascertain whether GIT1 was contained in the
mTORC1 or C2 complex, Raptor (mTORC1) and Rictor
(mTORC2) immunoprecipitations were performed.While
mTOR and mLST8 were contained in both Raptor and
Rictor immunoprecipitations, GIT1 was not found in
either mTOR complex (Fig. 2E), and Raptor and Rictor
were not found in GIT1 immunoprecipitations. Fur-
thermore, mSIN1 and PRAS40 were also not found in
GIT immunoprecipitations (Supplemental Fig. S2E).
These data demonstrate that GIT1 is not a component
of either of the two established mTOR complexes and
likely belongs to a newly identified mTOR complex con-
taining GIT1 and β-PIX (but lacking Raptor, Rictor,
mSin1, PRAS40, and mLST8).
To identifyGIT1 residues important formTORbinding,
293T cells were transfected with full-length epitope-
tagged mTOR and GIT1 deletion constructs. Following
myc-mTOR immunoprecipitation, full-length GIT1 and
GIT1 fragments containing residues 250–770 or 420–770
as well as the deletion mutant missing residues 264–430
(delSHD)boundmTOR(Fig. 2F). In contrast,GIT1contain-
ing residues 1–420 did not associate with mTOR, de-
monstrating that GIT1 binding to mTOR requires GIT1
residues 420–770, encompassing the synaptic localization
domain (SLD) and paxillin-binding domain (PBD). Finally,
to define the mTOR residues critical for GIT1 binding,
293T cells were transduced with epitope-tagged full-
length GIT1 and mTOR deletion fragments. mTOR frag-
ments containing residues 1271–2008 and 1750–2549,
but not residues 1–1482, boundGIT1 (Fig. 2G), demonstra-
ting that GIT1 binds mTOR between residues 1482 and
2008 within the FRAP, ATM, and TRAP (FAT) domain.
To determine howGIT1 binding to mTOR is regulated,
we focused on one tumor suppressor protein that operates
through the mTOR pathway and is essential for glioma
pathogenesis. The NF1 protein neurofibromin suppresses
astroglial growth by inhibiting RAS activation of AKT-
mediated mTOR signaling (Sandsmark et al. 2007; Bane-
rjee et al. 2011; Kaul et al. 2015) such that neurofibromin
loss results in increased (1.7-fold) astrocyte proliferation
and S6 (phospho-S6Ser240/244; 2.2-fold) activation (Fig.
3A). In Nf1−/− astrocytes, there was a 2.5-fold decrease
in GIT1 binding to mTOR relative to wild-type astrocytes
(Fig. 3A). Since GIT1 binding to mTOR requires residues
420–770, containing a putative phosphorylation residue
(Tyr544), GIT1 phosphorylation was examined. No change
in GIT1Tyr544 phosphorylation was observed following
Nf1 loss (Supplemental Fig. S3A), excluding this residue
as the regulatory phosphorylation site responsible for
GIT1 binding to mTOR.
Figure 1. mTORcomplexcompositioniscell type-specific. (A)Repre-
sentative immunoblots demonstrate littleDeptor andProtor-1 expres-
sioninwild-typemouseastrocytesandfibroblasts relativetoHEK293T
(293T) cells. Immunoblots frommTOR immunoprecipitations reveal
Rictor, Raptor, mSIN1, PRAS40, and mLST8 in wild-type astrocytes
(B) and fibroblasts (C ). Rb IgG was included as an internal control for
nonspecific binding. (D) While Raptor (mTORC1) immunoprecipita-
tions containedmTOR, Raptor, PRAS40, andmLST8 (but not Rictor),
Rictor (mTORC2) immunoprecipitations contained mSIN1 and
mLST8 but lacked Raptor and PRAS40 in wild-type astrocytes.
Smithson and Gutmann
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Because neurofibromin controls mTOR function in an
AKT-dependent manner, the impact of its inhibition
onGIT1/mTOR bindingwas assessed. First, GIT1 binding
to mTOR was increased following treatment with 10 nM
rapamycin (2.5-fold) (Fig. 3B), suggesting that conforma-
tional changes in mTOR resulting from rapamycin/
FKBP12 binding to the adjacent FRB domain might be re-
sponsible for this effect. Second, pharmacological AKT in-
hibition (50 nM MK2206) decreased mTOR (S6Ser240/244
phosphorylation) and AKT (AKTThr308, PRAS40Thr246,
and GSK-3βSer9 phosphorylation) activation in Nf1−/− as-
trocytes (Fig. 3C) and also resulted in increased (3.9-fold)
GIT1 binding to mTOR, establishing that GIT1 binding
to mTOR is mediated by AKT/mTOR activation. This
increase in GIT1 binding to mTOR following AKT inhi-
bition was not observed in wild-type astrocytes (Sup-
plemental Fig. S3C). Importantly, no change in GIT1/
mTOR binding was observed following MEK inhibition
(PD901) (data not shown) in Nf1−/− astrocytes. Third,
since AKT regulates GIT1 binding to
mTOR, we sought to determine
whether two mTOR phosphorylation
sites (Ser2448 and Ser2481) (Peterson
et al. 2000; Sekulic et al. 2000) were
regulated by mTOR/AKT activation.
No changes in mTOR Ser2448 and
Ser2481 phosphorylation were ob-
served in Nf1−/− astrocytes relative
to their wild-type counterparts (Sup-
plemental Fig. S3B), excluding this po-
tential mechanism. However, it is
possible that other phosphorylation
sites exist for which antibodies are
currently unavailable.
To determine whether GIT1 is re-
quired for neurofibromin-mediated as-
trocyte growth, three independently
generated mouse-specific Git1
shRNA (shGit1) constructs were eval-
uated, and the two with the greatest
knockdown in wild-type (3.1-fold and
3.5-fold reduction) and Nf1−/− (2.5-
fold and 2.1-fold reduction) astrocytes
were selected (Fig. 4A). Following
shGit1 knockdown, Nf1−/− astrocyte
growth was reduced to wild-type lev-
els, with no effect on wild-type astro-
cytes (Fig. 4B; Supplemental Fig. 4A).
This reduction in cell growth was the
result of increased cell death (apopto-
sis), as revealed by an increase in clea-
ved caspase-3 levels (Supplemental
Fig. S4B) and the percentage of
TUNEL+ astrocytes (Fig. 4C). No
change in LC3A/B expression (autoph-
agy) was observed (Supplemental Fig.
S4B). As before, no change in cleaved
caspase-3 levels or the percentage of
TUNEL+ cells was observed following
shGit1 knockdown in wild-type astro-
cytes (Supplemental Fig. S4C).
GIT1 was initially identified as a G-
protein-coupled receptor kinase 2-
binding protein (Premont et al. 1998)
and has been implicated in the control
of receptor trafficking, protein com-
plex assembly/transport, focal adhesion turnover, synapse
formation, cell motility, and cell growth (Zhao et al. 2000;
Manabe et al. 2002; Za et al. 2006). GIT1 can also act as a
GTPase-activating protein for the ADP ribosylation factor
family of small GTPases (Claing et al. 2000; Vitale et al.
2000), including Rac1 (Zhang et al. 2005; Chang et al.
2015), by binding to the C-terminal region of the Rho gua-
nine nucleotide exchange factor 7 (ARHGEF7 or β-PIX)
and promoting the interaction of β-PIX with Rac1 (Bagro-
dia et al. 1999; Zhang et al. 2005; Fiuza et al. 2013). How-
ever, we observed no reproducible changes in Rac1
activity following shGit1 knockdown (Supplemental Fig.
S4D), and β-PIX knockdown did not alterNf1−/− astrocyte
proliferation (data not shown). In addition, GIT1 has been
implicated as a Hippo pathway regulator; however, no
change in YAP levels or YAP phosphorylation (Ser137)
was observed in Nf1-deficient astrocytes before or after
shGit1 knockdown (Supplemental Fig. S4E). Since GIT1
is an mTOR-binding protein, it is possible that reduced
Figure 2. GIT1 is a novelmTOR-binding protein in astrocytes. (A) Proteomic analysis ofmTOR
immunoprecipitations from wild-type astrocytes reveals several potential mTOR-binding pro-
teins. (B) Validation of mTOR-binding proteins with spectral counts of ≥10 by immunoblot re-
veals that endogenous GIT1, but not TGM2 or RhoC, associates with mTOR. Rb IgG was
included as an internal control for nonspecific binding. (C ) GIT1 and mTOR binding is also ob-
served in GIT1 immunoprecipitations from wild-type astrocytes. (D) Full-length Flag-tagged
GIT1 (Flag-GIT1) and myc-tagged mTOR (myc-mTOR) associate in HEK293 cells. Flag-pCMVg
(empty vector) was used as a control. (E) GIT1 is not found in Raptor (mTORC1) or Rictor
(mTORC2) immunoprecipitations by immunoblot. Raptor, Rictor, and mLST8 are not con-
tained inGIT1 immunoprecipitations. (F ) Full-lengthmyc-mTOR binding to Flag-GIT1 requires
GIT1 residues 420–770 (dotted outline) containing the paxillin-binding domain (PBD) and a por-
tion of the synaptic localization domain (SLD). ANK denotes the ankyrin repeats, while SHD de-
notes the Spa2 homology domain. (G) Full-length Flag-GIT1 binding to myc-mTOR requires
mTOR residues 1482–2008, encompassing the mTOR FRAP, ATM, and TRAP (FAT) domains.
GIT1 mediates mTOR-dependent growth
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GIT1–mTOR association results in either increased Rap-
tor (C1) or Rictor (C2) binding to mTOR or increased
mTORC1/C2 effector activation. However, there was no
change in Raptor or Rictor binding to mTOR following
Nf1 loss/AKT activation (Fig. 3A), and no changes in the
activation of known mTORC1 (4EBP1) or mTORC2
(SGK1 and PKCα/β-II) effectors were observed before or af-
ter shGit1 knockdown in Nf1-deficient astrocytes (Sup-
plemental Fig. S4E). Collectively, the findings reported
here suggest that GIT1/mTOR binding likely sequesters
GIT1 from activating its currently unidentified down-
stream effectors to mediate astrocyte survival (Fig. 4E).
Future studies will be required to identify these signaling
intermediates.
Taken together, the identification of a new GIT1/
mTOR complex in this study raises several important
points relevant tomTOR composition and function. First,
mTOR creates a level of functional diversity by interact-
ing with unique binding partners in different tissue types.
In this regard, we reported previously that mTOR com-
plex composition and function in NSCs are dictated by
brain region-specific differences in Rictor expression
(Lee da et al. 2010). Similarly, while Deptor regulates
mTORkinase activity in HEK293 cells, it is not expressed
in wild-typemouse astrocytes and fibroblasts. Loss of Pro-
tor-1 expression decreases N-myc downstream-regulated
gene-1 (NDRG1; mTORC2 effector) activation in the kid-
ney but not in the brain (Pearce et al. 2011). As such, the
differential expression of mTOR-interacting proteins
in various tissues and species (Pearce et al. 2011; Yuan
et al. 2015) or cell lines (Sarbassov et al. 2004; Foster
et al. 2010) may partly explain potentially conflicting re-
sults obtained when studying mTOR
in different tissue types or cell popula-
tions. Second, mTOR function is also
dictated by the formation of at least
two functional complexes containing
distinct binding partners. While two
distinct mTOR complexes (mTORC1
and mTORC2) were identified in as-
trocytes, we describe for the first
time the existence of a third mTOR
complex composed of GIT1 and β-
PIX but not Rictor or Raptor. Support
for additional mTOR complexes de-
rives from studies examining oxygen-
induced mTOR-mediated translation-
al activation of terminal oligopyrimi-
dine (TOP) mRNA in fibroblasts
(Miloslavski et al. 2014), where
mTOR regulation of TOP mRNA
translation was independent of Rictor
or Raptor and occurred in the absence
of S6K and 4EBPI activation. Addition-
ally, rapamycin inhibition of mSin1
phosphorylation in human rhabdo-
myosarcoma cells was mimicked by
mTOR or mLST8 silencing but not
by Raptor, Rictor, S6K1, or AKT loss
(Luo et al. 2015), suggesting the pres-
ence of a new mTOR complex con-
taining only mSIN1 and mLST8.
Third, mTOR function can be regulat-
ed by different upstream modulators.
As such, we showed previously that
Pten and neurofibromin loss have sim-
ilar effects onmTOR activation and proliferation in astro-
cytes, whereas tuberin/hamartin loss activates mTOR
through Rheb and does not result in increased astrocyte
growth (Banerjee et al. 2011). Moreover, Nf1+/− mice
with somatic Nf1 gene inactivation in astroglial progeni-
tors develop optic gliomas, whereas Nf1+/− mice with
Rheb expression in astroglial progenitors do not develop
optic gliomas despite robust mTOR hyperactivation.
In summary, these studies establish that the molecular
composition and function of mTOR can be cell type-spe-
cific and identify a novelmTORcomplex critical for astro-
cyte survival. These findings have important implications
for the interpretation of future mTOR functional studies
in distinct tissues relevant to the design and execution




Nf1flox/flox (wild-type) mice were generated and maintained as previously
described (Zhu et al. 2001; Bajenaru et al. 2002). Mice were used in strict
accordance with an approved animal studies protocol at the Washington
University School of Medicine.
Cell culture
Wild-type and Nf1-deficient (Nf1−/−) astrocytes were generated from the
brainstems of P1–P2 mouse pups, and Nf1 gene inactivation was per-
formed using adenovirus type 5 (Ad5) (University of Iowa Gene Transfer
Vector Core, Iowa City, IA) as previously described (Sandsmark et al.
2007). Fibroblasts were prepared from small ear sections from P1–P2
Figure 3. Neurofibromin loss decreases GIT1 binding tomTOR. (A) Neurofibromin loss results
in increased astrocyte growth and mTOR activation (phospho-S6S240/244) relative to wild-type
controls. Reduced GIT1 binding to mTOR is observed inNf1−/− relative to wild-type astrocytes.
Scatter plots illustrate independently generated mTOR immunoprecipitations. Treatment with
the either 10 nM rapamycin (B) or 50 nMMK2206 (C ) increasesGIT1 binding tomTOR inNf1−/−
astrocytes. mTOR and AKT inhibition were confirmed by decreased S6 (phospho-S6Ser240/244),
AKT (phospho-AKTThr308), PRAS40 (phospho-PRAS40Thr246), and GSK-3β (phospho-GSK-
3βSer9) phosphorylation. (∗) P < 0.05; (∗∗) P < 0.005.
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wild-type pups dissociated in collagenase type I-A. All cells were serum-
starved for 48 h prior to analysis, and neurofibromin loss was confirmed
by Western blot. 293T cells (3 × 106 cells) maintained in complete
DMEMwere incubated in antibiotic-free DMEM 5 h prior to transfection.
Western blotting
Cells were lysed in 0.3%CHAPS buffer containing 40mMHEPES (pH 7.4)
(Gibco), 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM β-glycero-
phosphate, and protease inhibitors. Western blots were performed as
described previously (Uhlmann et al. 2004) using primary antibodies (Sup-
plemental Table S1) and horseradish peroxidase-conjugated affinity-
purified secondary antibodies (1:5000; Cell Signaling Technology) by en-
hanced chemiluminescence-based detection (Pierce).
Immunoprecipitation
Precleared protein lysates (200–300 µg; 0.3%CHAPS buffer) were incubat-
ed for 16–18 h with primary antibodies (Supplemental Table S1) or normal
rabbit IgG (Rb IgG; control) and immunoprecipitated using protein G
beads. Bead/protein complexes were washed three times with 0.3%
CHAPS buffer containing 120 mMNaCl2 and eluted in 2× Laemmli buffer
prior toWestern blot analysis. Rapamycin (10 nM)was included during the
immunoprecipitation incubation step to inhibit mTOR. For 293T cells,
mTOR immunoprecipitations were performed using 600–800 µg of input
protein with and without fetal bovine serum (FBS).
Proteomic analysis
Precleared lysates (1.3 mg) from wild-type astrocytes were processed for
immunoprecipitation as described above. Flash-frozen elutes were separat-
ed by SDS-PAGE on 10%Bis-Tris NuPAGE gels (Invitrogen) and processed
by in-gel digestion with trypsin at 37°C for analysis by nanoscale liquid
chromatography coupled to tandem mass spectrometry (MS Bioworks).
Resulting peptides were identified using Mascot and filtered using a 1%
protein and peptide false discovery rate and requiring at least two unique
peptides per protein. Peptides are listed by descending spectral counts
(protein abundance) with their accession number and molecular weight
(Supplemental Table S3).
Viral production
293T cells were transfected with 10 µg of each protein fragment (Supple-
mental Table S2; Yin et al. 2004) in Opti-MEM (Gibco) using X-treme-
GENE 9 (Roche). Mouse-specific Git1 shRNAi lentiviral constructs
(shGit1) (Sigma Mission, TRCN0000346581 and TRC0000346504) were
generated following 293T Fugene HD-mediated transfection with 10 µg
of shGit1, 5 µg of pMD1, 2.5 µg of Rev, and 3 µg of pCMVg (Supplemental
Table S2). Filtered virus was applied to astrocytes in 0.6 µL/mL Polybrene
(Millipore). pLKO-anti-GFP lentivirus was used as a control.
Pharmacological inhibitors
Cells were treated in serum-free medium with 10 nM rapamycin (LC Lab-
oratories), 50 nM MK2206 (Selleck), or 1 nM PD901 (Selleck) for 18 h (for
proliferation) or 2 h (for Western blot).
Cell proliferation
Astrocytes were serum-starved for 48 h and analyzed following 20 h of ex-
posure to bromodeoxyuridine (BrdU) (Roche). Following the manufactur-
er’s instructions, fixed cells were incubated with peroxidase-conjugated
anti-BrdU antibodies and developed in tetramethyl-benzidine. Optical ab-
sorbance was measured at 450 nm using a microplate reader (Bio-Rad).
Apoptosis
Astrocytes were permeabilized in PBS containing 0.1% Triton X-100 and
0.1% sodium citrate. Apoptosis was detected using an in situ cell death
kit (Roche), withDNase included as positive control.Nuclei were counter-
stained with 0.005% bis-benzimide (Sigma). Images were captured using
a fluorescence microscope (Leica), and apoptotic cells were quantified by
direct cell counting using ImageJ.
Statistical analysis
All in vitro studies were repeated at least three times with comparable
results. Data were analyzed using parametric Student’s t-test or one-way
ANOVA in GraphPad Prism 5. Significance was set at P < 0.05.
Proteomic data will be deposited in Gene Expression Omnibus at the
time of publication.
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Figure 4. Neurofibromin-mediated astrocyte survival operates in an
mTOR/GIT1-dependent manner. (A) Git1 knockdown using two in-
dependently generated mouse-specific RNAi (shGit1) lentiviruses re-
duces GIT1 expression in wild-type and Nf1-deficient (Nf1−/−)
astrocytes. (B) shGit1 knockdown decreases Nf1−/−, but not wild-
type, astrocyte proliferation relative to (vector) controls. (C ) shGit1
knockdown increases apoptosis (“% TUNEL+ cells”; arrows denote
TUNEL+ cells). (D) Proposed mechanism for GIT1-mediated neurofi-
bromin/mTOR-regulated astrocyte survival.While neurofibromin in-
hibits AKT/mTOR/GIT1-mediated astrocyte growth (left panel),
neurofibromin loss leads to an AKT/mTOR-dependent reduction in
mTOR/GIT1 binding, which results in increased astrocyte survival
(middle panel). (Right panel) Genetic and pharmacological inhibition
of AKT, mTOR, or GIT1 reduces astrocyte survival. (∗) P < 0.05; (∗∗)
P < 0.005; (∗∗∗) P < 0.0005.
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